WEC
LGND icon

Winslow Evans & Crocker’s Ligand Pharmaceuticals LGND Stock Holding History

Winslow Evans & Crocker’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16
Closed -$2K – 1254
2019
Q1 		$2K Buy
+16
New +$1.21K ﹤0.01% 1185
2018
Q4 		– Sell
-3,687
Closed -$632K – 1119
2018
Q3 		$632K Hold
3,687
– – 0.19% 120
2018
Q2 		$478K Buy
3,687
+321
+10% +$35.8K 0.15% 146
2018
Q1 		$347K Buy
+3,366
New +$333K 0.11% 184

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Winslow Evans & Crocker's LGND Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 16 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in LGND in Q1 2018 and held it in 4 quarters. The position peaked at $632K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 16 Ligand Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Winslow Evans & Crocker first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Winslow Evans & Crocker's Ligand Pharmaceuticals position peaked at $632K in Q3 2018.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.